{
    "paper_id": "f508e125b0592b51a7ca2edf3ebcde80941640d4",
    "metadata": {
        "title": "",
        "authors": [
            {
                "first": "Daphne",
                "middle": [],
                "last": "Bottos",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Brent",
                "middle": [],
                "last": "Waggoner",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Corrie",
                "middle": [],
                "last": "Buchanan",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Joette",
                "middle": [],
                "last": "Busby",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Peter",
                "middle": [],
                "last": "Klln",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Michael",
                "middle": [],
                "last": "Ball",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Anthony",
                "middle": [],
                "last": "Inniss",
                "suffix": "",
                "affiliation": {},
                "email": ""
            }
        ]
    },
    "abstract": [
        {
            "text": "A Alkalinization Opt im izing management of tumor lysis syndro me in ad ults with hematologic ma lig nancies [M ich allet et all 2(3): 159-166 -cr Allopurinol Optim iz ing ma nagement of tumor lysis sy ndrome in adu lts with hematol ogic ma lignancies [Michalle t e t all 2(3): 159-166-cr",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Tumor lysis syndromein solid tumors [Men et all 2(3):188-191-case Am p hotericin B Appro aches to management of invasive fungal infec tions in patients with hematologic malignan cie s [Forr est and Wal sh] 2( 1):21-30-cr Analges ic J.ad der The role of methadone in the treatment of moderate to severe ca ncer pain [Shainva] 2(3):176-18U-cr Anem ia Weekly adm inistration o f cpoctin alfa improves cognitio n and qua lity of life in pat ients with breas t cancer recei ving chemot hera py [Chang et all 2(1P2-58-oc Treatment of anemia with erythropoietic agents in patients with hematologic malignancies [Straus] 2(4):2 15w224-cr Supportive ca re of elderly patients with cancer [Balducci] 2(4):225-228-cr Sex differences in patients who have cance r with mild anemia : sym ptom burden and quality of life [Schwartzberg et al] 2(4) :241-246-oc Anti bacterial Agents Moving beyo nd febrile neutropenia (Mo rri so n) [Lyma n an d Kuderer] 2(2):95-97\u00b7c omm Anti biotics An overview of the manage ment of infecti on and febrile neutropenia in patients with cancer [Morrison] 2(2):88-94-c r Mov ing beyon d febrile ne ut ro penia (Mo rrison) [Lyman and Kud er er] 2(2):95 -97-comm Antiemetic Agents A ran dom ized, multicenter, open-label compariso n of the antieme tic efficacy of dolasetron versus ondan setro n for the prevention of nausea and vomiting during high-dose myeloablative chemotherapy [Mandanas et al l 2( 2)0114-1 21-oc Chemothe rapy-induced emesis: qual ity of life and economic impact in the context of current practice in Canada [Lachainc ct al)2(3):181-187-oc Antifungal Agents Invasive fungal infections in patients with hematologic malignanc ies: the next steps (Forrest and Walsh) [Glasmacbcr ] 2(J):31 -33-comm A n overview of the man agement of infecti on and febrile neutropenia in patients with cancer [Morrison) 2(2):88 -94-cr Antimycotic Therapy Invasive fungal infections in patie nts with hema tologic malignanc ies: the next steps (Forrest and Walsh) [Glasmacher] 2(l):3 1-33-comm Aspergillosis Approaches to management of invasive fungal infections in patients with hematologic maligna ncies [Forrest and Walsh] 2(1):2 1-30-cr Asp ergillus Species An overview of the management of infect ion and febrile neutrop enia in patients with cancer [Morrison] 2(2):8R-94-cr Axial Back Pain Supportive care aspect'> of vertebroplasty in patients with ca ncer [Wu and Fourney] 2(2):98-104-cr Azoles Approaches to management of invasive fungal infections in patients with hemato logic malignancies [Forrest and Walsh] 2(1):2 1-30-cr c Cancer Care Mo nitor A comb ined analys is of average relative dose intensity in the chemotherapy of solid tumors with pegfilgras tim or filgrastim support [Crawford et al] 2(4): 229 -233-oc Sex differences in patients who have cancer with mild anemia: symptom burden and quality of life [Schwartzberg et all 2(4):241-246-oc Candida species Approaches to managemen t of invasive fungal infections in patients with hematologic maligna ncies [Forrest and Walsh] 2(1):2 1-30-cr An overview of the management of infection and febr ile neutropen ia in patients with cancer [Morrison] 2(2):88-94-cr Capecitablne Supportive care of elderly patients with cancer [Balducci] 2(4):225-228-cr Ce ment Extravasatio n Suppo rtive care aspects of vertebroplasty in patients with cancer IWu and Fourney ] 2(2):98-104-cr Ce ment Injection A brie f upd ate on the biomechanlsms underly ing cement inje cti on and le akage in vcrt cbroplasty (Wu and Fo urney) [Barou d] 2(2 ):105-108comm Ceme nt Leakage A brief update on the biomechanisms underlying cement injection and leakage in vertebroplasty (Wu and Fourney) [Baroud] 2(2):105-10S-comm KEY TOABBREWAnONS case -case report comm-commentary cr -comprehensive revi ew ed -editorial mh -meeting highlights ocoriginal contribution rib -research in brief tmtranslational medicine Oumed, published. and",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": " (2)",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "A co mbined analysis of averag e relative dose intensity in the ch emot herapy of solid tumors with pcgf ilgrasd m or f ilgrastim suppor t",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Green",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "2",
            "issn": "",
            "pages": "229--233",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "A randomized, multicenter, open-labe l co mparison of the ant iemetic efficacy of dolasetron vers us onda nse rron for the prevent ion of nau sea and vomiting during high-dose mye loab lative che motherapy IMandanas et al",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "G Ree Nspan",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "2",
            "issn": "",
            "pages": "114--126",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Single-dose prevention or short-term treatment with fibroblast growt h factor-20 (CG53135-05) redu ces the seve rity and dura tion of ora l muco sitis",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "2",
            "issn": "",
            "pages": "22--127",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Tumor lysis syndrome in solid tumors",
            "authors": [],
            "year": null,
            "venue": "Mon et 31)",
            "volume": "2",
            "issn": "3",
            "pages": "188--191",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Impa ct of severe acute respiratory syndrome on patie nt access to palliative rad iation therapy",
            "authors": [],
            "year": null,
            "venue": "Lee et all",
            "volume": "2",
            "issn": "2",
            "pages": "109--120",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Chemotherapy -induced emesis: quality of life and eco no mic impact in the context of current practice in Canada",
            "authors": [],
            "year": null,
            "venue": "Lachai ne et all",
            "volume": "2",
            "issn": "3",
            "pages": "18--19",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Sex differences in patients who have cancer with mild anem ia: sy mptom burden and quality of life",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "C"
                    ],
                    "last": "Ilou Ts",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "J Joud i",
            "volume": "2",
            "issn": "4",
            "pages": "24--25",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Chemot herapy-induced emes is: qu ality of life and economic impact in the context of current practice in Ca nada",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Cr K Katz Er",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Lac haine et all",
            "volume": "2",
            "issn": "1",
            "pages": "181--187",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "The volume/ou tco me relationship in urologic cancer surger",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Kcnety",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Joudi an d Koncty)",
            "volume": "2",
            "issn": "1",
            "pages": "42--46",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "-comm A primer in prognostic and predictive mod els: developmen t and validation of neutropen ia risk models",
            "authors": [],
            "year": null,
            "venue": "M ovin g beyond febril e neut rop enia (M orrison )",
            "volume": "2",
            "issn": "",
            "pages": "168--175",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "Che motherapy-induced emes is: quality of life and eco nomic impact in the contex t o f curre nt practice in Ca nada",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "2",
            "issn": "",
            "pages": "181--187",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "Benefit s of GM-CS F versu s placebo or G-CSF in reduci ng chemotherap yinduced com plicat ions : a systematic review of the literature",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "Y"
                    ],
                    "last": "Lao",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Oc Lec",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "H"
                    ],
                    "last": "Lyman",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Weekly administration of epoeti n alfa improves cog nition and quality of life in patients wit h breast ca ncer rec eiving che mot he rapy",
            "volume": "2",
            "issn": "",
            "pages": "1--22",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "Supportive care aspects of vertebroplasty in patients with cancer (Wu and Fourney ) 2(2):98\u00b7 104-cr y Yell e, L. Chemo therapy-induced emesis: quality of life and economic impact in the co ntext of curren t practice in Canada",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "S"
                    ],
                    "last": "Wu",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Lachaine et all",
            "volume": "2",
            "issn": "3",
            "pages": "18--19",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "Weekly administration of epoctin alfa improves cog nition and quality of life in patients with breast cancer receiving chemotherapy",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "D"
                    ],
                    "last": "Young",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Chang et all",
            "volume": "2",
            "issn": "",
            "pages": "52--58",
            "other_ids": {}
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "Survival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic acid in patients with bone metastases fro m solid tumors",
            "authors": [],
            "year": null,
            "venue": "Maj or et all",
            "volume": "2",
            "issn": "4",
            "pages": "234--240",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "upd ate on the biomechanisms un derlying cem ent injection and leakage in vertebroplasty (WU and Fourney) [Baroud] 2(2): 105\u00b710 8-conun Bisp hosphonates Survival-adjuste d multiple-event anal ysis for the evalua tion of treatment effects of zoledronic acid in patients with bone metastases from solid tumors [Major et all 2(4):234\u00b72 40-oc Bone Metastases Surv ival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic acid in patients with bone metastases from solid tumors [Major et al)2(4):234-240-oc Breast Ca ncer Weekly administration of epoetin alfa improves cognition and quality of life in patients with breast cancer rece iving chemothera py [Chang ct al] 2(1):52-58-oc A rand omi zed, m ultice n ter, ope n-la be l com parison of the an tiemetic efficacy of dolasetron versus o ndanset ro n for the prevention of nausea and vomiting during high-dose myeloabl ative chemot herapy [Mandanas et al]2(2): 114-121-oc Tumor lysis syndrome in solid tumors [Matt et al] 2(3): 188\u00b7191 -case Surv ival-adj usted multip le-eve nt analysis for the evaluat ion of treatment effects of zoledroni c acid in patients with bone metastases from solid tumors (Major et all 2le-do se preventi on or sho rt-term trea tme nt with fibro blast growt h factor-20 (CG53 135\u00b7 05) reduces the severity and duration of oral mucositis [Alvarez et al] 2(2):122-I 27-trn Chemotherapy-induced eme sis: qu ality of life and economic impact in the context of current practice in Canada [Lachaine et all 2(3):18t -187-oc Tumor lysis syndrome in solid tumors [Mott er al] 2(3): 188-191 -case Treatment of anemia with erythropoietic agents in patients with hematologic malignancies [Strau s} 2(4) :2 15-224-cr A com bined analysis of average relative dose intensity in the chemotherapy of solid tumors with pcgfilgrastim or til grastim support [Cr awford et al] 2(4):229-233-oc Ch emo therapy-I nduced C om plications Benefits of GM -CS F versus place bo or G-CSF in reducing chemo therapyinduced co mplic ations : a systematic review of the literatu re [Dubois ct al] 2(1):34-4 1-<:, Cli nic Interventions Exploring the breadth of supportive cancer care issues [Crawford] 2(2):77-78-00 Coenltion Weekly admi nistration of epoeti n alfa improves cog nition and quality of life in pa tien ts with breas t ca nce r receiving che mo the rapy [C ha ng et al] 2(1 ):52 -58-\u00ab Co nsti pa tion Management of con stipation in patients with cancer [Tho mas and vo n Gu nten] 2(",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "Fa tig ueA combined analy sis of average relative dose intensity in the chemot herapy of solid tumors with pegfilgrastim or f ilgrastim support [Craw ford et al) 2(4):229 -233-oc Sex differences in patie nts who have ca nce r with mild anemia: symptom burden and quality of life [Schwartzberg ct al] 2(4):24l -246-oc Febrile Neu tro p enia Benefits of GM -CSF versus placebo or G-c s r in red ucing ch emothe rapyind uced complica tion s: a systematic review of the literature [Dubois et al] 2( 1):34-4 1-<:, An ove rview of the management of infection and feb rile neutropenia in patients with cancer [Morrison ) 2(2):88-94 -cr M ovin g bey on d febrile neutrop enia (Mo rrison) [Lyman and Kuderer ] 2(2):95-97-comm Fe ver Benefits of G M\u00b7CSF vers us placebo or G-CSF in reducing chemo thera pyind uced co mplica tions: a systematic review of the literature [Duboi s er al] 2(1):34-41-<:, Fibroblas t Growth Factor-20 S ingle-dose prevention or s hort-te rm treatm en t wi th fibrob las t gr owt h factor-20 (C G53 135-05) red uces the severity and duration of ora l mucositis [Alvarez et al] 2(2):122-127-tm Filgrasti m Supportive care of elde rly patie nts with cancer [Balducci] 2(4) :225-228-e r A combined analysis of averagerelativedose intensityin the chemot:hernpy of solid tumorswith pegfilgrastim or filgrastimsupport [Crawford eI a1) 2(4):229-233-oc S\u00b7 fluoroura cil Single-dose prevention or sho rt-te rm tre atment wit h fibroblast grow th fact or-20 (CG 5 3 135-05) re duces the severity and duratio n of oral mucositis {Alvarez ct al] 2(2):122-127-tm SHT 3 Receptor Antagon ists A random ized, m ult icenter , open-l abe l compa rison of the antie me tic efficacy of dolasetron versu s ondansetron for the preve ntion of nausea and vomiting during high-dose myeloablative chemot hera py [Mandanas ct al] 2(2):114-121-oc F racture Rlsk Supportive care aspects of verteb ropla sty in patients with ca ncer [Wu and Fourney )2(2):98-104-cr F un ctiona l Assessment of Cancer Therap y Scale T re atm e nt o f an em i a w i t h e ry thro poie ti c ag e n ts i n pati en ts w it h hematologic malignancies [Straus]2(4):215\u00b7 224-cr Fu nction al Li vin g Ind ex C hemo therapy-induced emesis: quality of life and economic impact in the co ntext of current practice in Can ada [Lachaine et al] 2(3 ): l8 1-187-oc",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "ca re of elderly patients with cancer (Balducci] 2(4):225-228-cr Gram-Positive Isolates An overview of the management of infection and febrile neutropenia in patient s with cancer [Mo rriso n] 2(2):88 -94 -cr Granuloc yte Colcny-S tlm ulatl ug Factor Benefits of GM -CSF versus placebo or G-CS F in reducing chemo thera pyinduced compli cations: a systematic review of the literature [Dubois et al] 2(1):34 -41-cr H Hea lt h Utility Index Weekly administration of epoctin alfa improves cognition and quality of life in patients withbreastcareer receivingchemotheropy [Chang et all 2(1):.52-58-oc Hema tolog ic Malignancies Approaches to management of invasive funga l infections in patients with hema tolog ic ma lignancies [Forrest and Walsh] 2(1):2 1-30-cr Invasive fung al infecti ons in patient s with hematologic m alignancies : the next steps (Forrest and Walsh) [Glasmacher] 2(1):31-33-comm An overview of the management of infectio n and febri le neu tropenia in pat ients with cancer (Morri son ] 2(2):88-94-cr A random ized. multicen ter. open-labe l co mp ari son of the antie me tic efficacy of dolasetron versus ondansetron for the preven tion of nausea and vo miting during high-dose rnyeloablauve chemotherapy [Ma ndanas et . 11 2(2): 114-12 1-oc Optimi zing management of tumor lysis syndrome in adults with hematologic malig nancies [Mlchallet et al] 2(3 ):159-l66-cr Patient se lection and treatment of tumor lysis sy ndrome in adult s wi th hematologic malignancies (Michallet et all [Go ldman) 2(3):167-comm Treatment of anemia with ery thropoietic agents in patients with hematologic maligna ncies (Straus] 2(4):215 -224\u00b7 cr Hematopoieti c Growth Factors Moving beyond febr ile neutr openia (Morrison) [Lyman and Kude rer] of the management of infe ction and febrile neutropenia in patients with cancer (Morrison] 2(2):88-94-cr Hem oglobin Weekly administration of epo etin alfa improves cogn ition and quality of life in patients with breast ca ncer receiving chemotherapy [C ha ng er al) 2(1 ):52-58-oc Treatment of anemia with erythropoietic agents in patients with hem atologic malign ancies [Straus] 2(4) :2 15-224-cr A comb ined analysis of average relative dose intensity in the chemothera py of so lid tumors with pegfilgrastim or filgra stim support [Craw ford et al) 2(4):229 -233-oc Sex differences in patients who have ca ncer with mild anemi a: symptom burden and quality oflife [Schwartzberg et al] 2(4):241-246-oc Hospital Volum e The volume/outcome relation ship in urologic ca ncer surge ry [Jc udi and Konety] 2( 1):42-46-cr Hyd ra tion Optimizing managemen t of tumor lysis syndrome in adults with hematologic malign ancies [Michallet et all 2(3) :159\u00b7166<r Hyd romorphone The role of met hadone in the treatment of moderate (0 severe cancer pain [Shaiova] 2(3): 176\u00b7 I80-cr Hyp er kal em ia Opti mizing managemen t of tumor lysis syndro me in adults with hematologic malign ancies [Michallet et all 2(3): 159\u00b7 166-cr Tumor lysis syndrome in solid tumors [Mott Cl all 2(3 ):188-19 1-case Hyperphosphatem ia Optimizing management of tumo r lysis syndrome in adults with hematolog ic malignancies [Micha llet et al] 2(3);159-166-cr",
            "latex": null,
            "type": "figure"
        },
        "FIGREF3": {
            "text": "ent of constipat ion in patients with cancer [Thomas and vo n Gunten]2(l):47-5 1-cr Leukemia Approaches to management of invasive funga l infec tions in patients with hematologic mal ignancies [Forrest and Walsh] 2(1 ):21-30-cr Lin ear An a log Scal e Assessment Treatm ent of anemia with erythropo ietic age nts in patients with hematologic malignancies (Strau s] 2(4) :215\u00b7224-cr Lu ng Ca ncer Tumor lysis syndrome in solid tumors [Mou et al] 2(3): l 88\u00b7 19l -case Survival-adjusted multiple-event analysis for the evaluation of tr eatment effec ts of zoledron ic acid in patient s with bone met astases from solid tum ors [Major et al] 2(4):234 -24O-oc M Medica l C osts Chemotherapy-induced emesis: quality of life and economic impact in the context of current practice in Canada [Lachaine et all 2(3): 18 J-187-oc Meeti ng I li~hlights Low-dose rasbur icase prophy laxis for prevention of tumor lysis-assoc iated hyperuricemia 2(2):79-80-mh Incidence of ne utropeni c events d uring the first cycl e of chemotherap y 2(2) :80-8 1-mh Relationship between erythropoiet in use and risk of thromboembolic events in rectal and gas tric cancers treated with c hem ora dia tion therapy 2(2):8 1-82-mh Epidemio logy of cat heter-related thro mbosis in ca ncer 2(2):82-83 -mh Ziconotide: a novel calcium chann el blocker for intract able pain 2(3):143 -IM-mh Preliminary report of the Zo meta\u00ae-Fcmara\u00ae adjuvant synergy trial in the prevention of bo ne loss 2(3):144 \u00b7145-mh Apr ep itant the rapy effectivel y red uce s vomiting in patients recei ving moderately emetogenic chemo therapy 2(3) :145\u00b7 ]46-mh Prophylactic vorico nazo le versus ltracon azole for invasive fungal infections in acute myel ogenous leukemia and myelodysplastic syndro me: a phase II study 2(3):146-148-mh Prophylactic pcgfilgrastim plus ciprofloxacin effectively prevents neoadju vant chemotherapy-induced febrile neutropenia in pati ents with breas t cancer 2(4 )203-204 -mhOa bnpenlin falls to impro ve analgesia In pat ie nts with che aspects of vertebroplas ty in patients with cancer [Wu and Fourney ] 2(2):98-104-cr Morphine The role of methadone in the treatmen t of mo derat e to severe cancer pai n [Shaiova] 2(3): 176-180-cr Mucositis Sing le-dose prevention or short-term tre atmen t with fibroblas t grow th fac tor-20 (CG53 135 -05) re du ces th e sev eri ty and dura ti on of ora l mucositis [Alvarez et al] 2(2) :122 -127-lm Supportive care of elder ly patien ts with cancer [Balducci] 2(4):225-228-cr Mu lliple Myeloma Supportive care aspec ts of vertebroplas ty in patie nts wi th cancer [Wu and FoumeY12(2):98-104-cr Mye loablative Chemotherapy A randomized , m ult ic enter , op en-lab el compariso n of the an tieme tic efficacy of dolase tron vers us ond ansetron for the preventio n of nausea and vo miting during hig h-dose myeloablative che mothera py [Mandanas et ,IJ 2(2): 1l 4-121-oc Myelodysplastic Syndrome Treatm ent of anemi a with erythropoietic age nts in patients with hema tologic malignanci es lStrausJ2(4):215 -224-crN Nausea A ran domize d, multice nter, ope n-la be l com pa ri so n of the an t ie met ic efficacy of do laset ron versus on dans etrcn for the prevention of nausea and vomi ting during high-dose myeloabl ative chem othera py (Mandana s et al] 2(2):1 14-121-o c Chemothe rapy -induc ed emes is: quality of life an d economi c imp act in the con text of current practice in Ca nada [Lachaine et all 2( 3): 18 1-187-oc Supp ort ive car e of elderly patie nts wi th can cer [Balducci] 2(4):225-228 -cr Neutropenia Ben efits of GM -CSF vers us place bo or G-CSF in reducing ch emotherapyinduced comp lication s: a systematic review of the lite rature [Dub ois e t , IJ 2(1):34 -4 1-c, A primer in prog nostic and pre dictive mode ls: development and valid ation of neutropenia risk models [Lyman and Kudererl 2(3):168-175-cr Neutropenic Infections Supportive care of elderly patients with cancer [Bald ucci) 2(4):225-228-cr N-Methyl-D-Aspartate Receptor Th e role of methado ne in the trea tment of mode rate to se vere canc er pain [Shaiova] 2(3): 176-180-cr Nonmyeloid Malignancies Benefits of GM-CSF vers us placeb o or G-CSF in reduci ng chemot herapyind uced complications : a systematic review of the literature [ndom ized , multice nter, open -la be l compariso n of th e ant iemetic efficacy of dolasetron versus ondansetron for the preventio n of nausea and vom iting during high-dose myeloablative c hemot hera py [M andanas et al] 2(2):114-121-o c Oploids M an agem ent of con s tipa tio n in pa tien ts with ca nce r [T hom as and von Gu nten] 2(1):47\u00b751-cr Th e role of methadone in the trea tmen t of modera te to severe cancer pain [Shaiova] 2(3): 176-18 0-cr Supp ortive care of elderly pat ie nts with cancer [Balducci] 2(4):22 5-228-cr Osmotic Age nts Management of constipatio n in patients with cance r [T homas and von Gun te n] 2(1):47 -g the breadth of supp ort ive cance r care issues [Crawf ord ] 2(2) :77-78-ed Th e role of methadone in the treatment of mod erate to severe cancer pain [Shaio va] 2(3): 176-180-cr Sup portive care of elderly patients with cance r [Balducci ] 2(4): 22S-22 8-cr Palliative Therapy Th e correlation among patients and health care profes sio nals in assessing functiona l status using the Kam ofsky and East ern Coop era tive Onco logy Group performa nce status scales [de Borj a et all 2(1) :S9-63 -oc Impac t of severe acute respiratory syndrome on patient access to pa lliative radiation ther apy (Lee ct al] 2(2) : I Ol)~l 13 \u00b7 oc Sing le -dose pr evention or shor t-term treatme nt wi t h fib rob la st grow th fac tor-20 (CGS 3 t 3S-0S ) re du ce s the severity a nd du rati on of oral mucosi tis [Alvarez et all 2(2): 122 -127-tm Pamidronate Survival-adju sted m ult iple-even t ana lysis for the evaluation of treatment effects of zole dron ic aci d in pati ent s with bone metastases from solid tumo rs [M ajor et al l 2(4):234-240-oc Pa tient Selection Patient se lectio n a nd treatmen t of tu mor ly si s syndro me in adult s with hematologic maligna ncies (Mi chaUet et al) [Goldma n] 2(3 ):t67-comm Patient Waiting Times Impact of severe acute respiratory syndrome on patien t acce ss to palliative radiation thera py [Lee et all 2(2): l09-11 3-oc Pegfilgras tim Sup portive care of elderly patients with cancer [Bald ucci ]2(4) :225-2 28-cr A combined analysis of average relative dose intensity in the chemotherapy of solid tumors with pegfilgrastim or f ilgrastim support [Crawford et all2(4):229-233-oc Peristalsis Manag e me nt of constipatio n in pa tients with cance r [T homas a nd von Gun ten] of meth adone in the treatment of moderate to severe can cer pain Shaiovaaspects of vertebro plasty in patien ts with ca ncer [Wu and Fourney] 2(2):98-104-cr Predictive Perfo rmance A primer in prognost ic and predictive models: deve lopment and valida tion of neutropenia risk model s [Lyman and Kudcrer] 2(3): 168-175-cr Pr ognostic Models A primer in progno stic and predi ctive mode ls: development and validatio n of neutropenia risk mod els [Lyma n and Kuderer] 2(3): 168-l 75 -cr Prophy lactic Therapy A ra ndo mi zed , m ult ice nte r, open -la be l comparison of th e an tiemetic efficacy of dolasetron versus ondansetro n for the prevention of naus ea and vomiting during high-dose myclo ablative che mothera py [Ma nda nas et al] 2(2):114-121-oe Tum or lysis syndrome in solid tumors [Mott et al] 2(3): 188-19J -case Supportive care of elderly pa tien ts with cancer [Balducci1 2(4) :225-228-cr A combin ed ana lysis of average relative dose intensity in the chemotherapy of solid tumors with pegfilgr astim or filgrastim support [Crawford et al] 2(4):229 -233-oc Prost at e Ca ncer Survival-adjusted multiple-eve nt ana lysis for the evaluation of tre atmen t effec ts of zcl edronic acid in patie nts with bone metastases from solid tumors [Major e t al] 2(4) :234 -240 -oc Q Qua lity of Life Weekly adm inistration of epoc tin alfa improves cognition and quali ty of life in patients with breast ca ncer receiving chemotherapy [Ch ang et all 2( 1):52-58-oc The correlation among patients and health care professio nals in assess y-induced emesis: qualit y of life a nd economic im pact in the context of curre nt practice in Ca nad a ll.achain e et al] 2(3): 181-187-oc Sex differences in patients who have cancer wi th mi ld anem ia: symptom burd en and qualit y of life [Schwartzberg et al] le-dose prevention or short-term treatment with fibroblast growth facto r-2 0 (CG53 135\u00b705) reduces the severity and dura tio n of oral mucositis [Alvarez et all 2(2):122-127-trn Radi cal Pros tat ectomy Impact of sever e acute respiratory synd rome on patient acce ss to palliative radiation therapy [Lee et aI1 2(2): 109-113-oc The vo lum e/ outcome relationship in urologic cance r surgery [Joudi and Konety] 2( l) :42-4 6-cr Rasbu ri ca se Optimi z i ng m anag e m en t o f tumo r ly s is s ynd rome in ad u lt s wi th hematologic malignanci es (MichaUet et al] 2(3) : 159-166-cr Tumor lysis sy ndrome in solid tumors (Mott et al] 2(3): 18S-191 -case Renal Fa ilu re Opt i mi zi ng m an age ment o f tu mor ly si s sy nd rome i n adu lt s wit h hem atologic malignancies [Michallet et al] 2(3):159 -166-cr Research In Brief Kyph oplasty in lhe man agement of cancer-associated vertebral compressio n fractures 2( 1): 11-13-rib Pre ven tion and manageme nt of osteo necrosis of the jaw associ ated wi th bisph ospbonate therapy 2( I): 14\u00b7 17\u00b7 rib Incidence of thromboe mbolis m and role of low mo lecular weight heparin in pro longing survi val in patients with adva nced malignancies 2( J):18-20-rib Palifermin is efficaciou s in reduc ing oral mucosit is indu ced by inten s ive ca nce r therapy 2(2):84-85 -rib Role of prop hylact ic quin olo nes in reduci ng febri le neutropenia in patients undergoi ng myelosuppressive chemotherapy 2(2 ):86-87 -rib Pegfilgrastim: recent adva nces in the prop hy laxis of che motherapy-induced neutropenia 2(3): 149-l52-rib Nov e l Ihrom bo poetin mimet ic agent s with p ote nt ia l to ame liorate che motherapy-induced throm bocyt openia 2(3): 153-155 -rib Im pact of erythrop oietic agen ts on survival of anem ic patients with ca ncer 2(3): 156-158-rib Defer asirox (ICL670; Exja de 8 ) , a novel orally available iron che lator for co rrection of tran sfusio n-associated iro n overload 2(4):208-2 11-rib Role of psychostimulants in the ma nagem ent of cancer-related fatigue in pa tients with advanced ca ncer 2(4) :2 12\u00b7214\u00b7 rib Res ource Utilization Impact of severe acu te respirato ry syndrome on patie nt access to palliative rad iation therapy (Lee et al] 2(2):109 -1 13-oc R isk Factors A pri mer in prognos tic and predictive model s: development and validatio n of ne utropenia risk models [Lym an and Kudere r] 2(3): 16S-175-cr Tumor lysis syndrome in solid tumors (Mon et all 2(3):IS8-19 1-case S Severe Acute Respiratory Synd rome Impact of se vere acut e res piratory syndrome on patie nt access to palliative radiation therapy [Lee et a1]2(2): 109-113-oc Selt-As sessment Th e co rrel atio n among patients a nd health care profess iona ls in assessing func tional status using the Karnofsky and Eastern Cooperative Onco logy Grou p performance status scales [de Borj a et al] 2( 1):59 -63-oc Seru m C reatinine Tumor lysis syndrome in solid tum ors (Mott et al] 2(3): IS8-19 1-ease Sex Differences Sex difference s in pat ient s who have cancer with mild anemi a: symptom burden and qu ality of life [Schwartzberg cr al] 2(4) :24 1-246-oc Short-Term Trea tment Si ng le-dose prevention or short-ter m treatme nt with fibrob las t g rowth fac to r-20 (C 0 53 J35 -0 5) red uce s the s e veri ty a nd d uration o f oral mucositis [Alvarez et al) 2(2): 122-127-tm Single-Dose P re vention Singl e-dose prev ention or short-ter m tr eat me nt with fibrob last grow th overview of the management of infec tio n and febrile neu tro pe nia in patien ts with ca nce r [Morri son ] 2(2):8S\u00b794-cr A rando mized , mu lt icen te r, ope n-l ab el com pa ris o n of the a ntie met ic efficacy of dolas etron versus onda nse tron for the prevention of nausea and vom iting during high -dose mycloab lative chem othe rapy [Mandana s et al]2(2): 114-12 1-oc S too l Softeners Man ageme nt of const ipa tion in pati e nts with ca nce r (Thomas and von Gunt en] 2(1):47-51-cr Surgeon Volume Th e volume/outcome relationsh ip in urologic ca nce r surge ry [Joudi and Konety] 2( 1):4246-cr Symptom Burden Sex differences in pat ients who have cance r with mild ane mia: symptom burden and quality of life [Schwartzberg et al] thebreadth of supportive cancercare issues[Crawford] 2(2):77-78-ed Toxicity Benefit s of O M-CS F versus placebo or G-CSF in red ucing chemotherap yinduced complications: a sys te matic review of the literature (Dubois et a1] 2( 1):34-4 1-cr Thc role of met hadone in the treatment of mode rate to severe cancer pain [Sh aiova] 2(3): 176-180-er Th mor Lysls Synd rome Opti m i zi n g m a n ag e me n t of tum o r ly s i s s y n d rome i n ad u lt s wi th he matologic malignancies [M ichallet et al] 2(3): 159-166-cr Pati en t selection and treat ment of tu mor lysis sy ndrome in ad ults wi th hematologic malignanc ies (Michallet er al) [Goldman] 2(3):l 67-comm Tumor lysis syndrome in soli d tumors [Molt et al] 2(3): 188-19 1-case u Urate Ox idase O p ti m i zi n g m a n ag e me nt o f t umo r lys i s synd rome i n adu lt s w it h he matologic malignancies [Michallet et al}2(3) : 159-166-cr Ur ic Acid Tumo r lysis syndro me in solid tu mors [Mott et al] 2(3): ISS-191 ---case Ur ologic Neoplas ms Th e volum e/outcom e rel ation sh ip in urologic cance r surgery [ive care aspects of vertebr oplasty in patient s with ca ncer [Wu and Fourne y] 2(2):98-104-cr A brief update on the biomechanisms underlying cement injection and leakage in vertebroplasty CWu a nd Fourney ) (Baroud ] 2(2): 105-IOS-comm Vomiting A ran dom ized. mu lti center, open -label co m pa ri so n o f the a nt ieme tic effi cac y of doJasetro n versus ondan setron for the preven tion of nause a and vomiting during high-dose myeloablative chem otherap y [Ma ndana s elal)2(2): 114-121 -<><: Chemotherapy-ind uced emesis: quality of life and econ omic impact in the con text of current practice in Can ada [Lachainc et al] 2(3): 1S1-187-oc z Zo ledronic Acid Surv ival-adjusted multi ple-e vent a nalys is fo r the evaluatio n of treat ment effects of zoled roni c acid in patients with bo ne met astases from solid tumors {Major et aI] 2(4):234-240-oc author index A Alva rez, E. Single -do se preve ntio n or short-term treatme nt wit h fi bro blas t grow th fact or-20 (CG53 135-05) red uces the severi ty and d uratio n of or al mucositis [Alvarez et all 2(2):122-127-tm Asma r, L. A rando mized , multicenter, open-labe l com parison o f the antiemetic efficacy of dolasetro n versus ondansetron for the prevention of nausea and vomiting du ring high-dose mycloaolative chemothera py [Mandan as el al]2(2): 114-121-oc B Bad amg arav, E. Benefits of G M~CS F versus place bo or G-CSr in red uci ng che motherapyinduced compli cations: a systematic review of the literature [Duboi s et al]2(1):34-4I -cr Baldu cci, L. Supportive care of elderly patient s with cancer [Balducci ) 2(4 ):225-228-cr Haroud, G. A brie f upda te on the bio mechanisms und er lying cement inj ec tion and leak age in vertebroplas ty (Wu and Fou rney ) [Baroud ] GM\u00b7 CSF versus placeb o or G\u00b7CSF in reduci ng chemotherapyinduced compli cations: a sys tematic review of the literatu re [Dubois et al] 2(1):3 4-41 -cr Beveridge, R. A randomize d, mult icenter, open-l abe l compar iso n of t he antiemetic effica cy of dolasetron versus ondansetron for the prevention of nausea and vom iting during high-dose rnyclo ab lative che motherapy [Mandanas et al] 2(2):114-l21 -oc Bovett, G. 111e correlation amo ng patients and health care professionals in assess ing functional status using the K arnofsky and Eastern Cooperative Onco logy Group performance statu s scales [de Borj a et al] 2(1):59\u00b7 63-oc C Cha kma kj ia n, C. Tumor lysis syndro me in solid tumors [Mott ct al] 2(3): 188-19 1-case C hang. cl. WeekJy adm inistration of epoetin alfa improves cog nition and quality of life in pat ie nts wi th breast cancer receiving chemotherapy [Chan g et alJ 2(1 ):52-58-oc Chen, B.I.. Su rvival-adj usted multiple-event analysis for the eva lua tion of treatment effects of zoled ronic acid in patients with bo ne metastases from solid tumors [Maj or et all 2(4) :234-24Q..oc C how, E. The corre lation amo ng patie nts and health care professionals in asse ssing functional s tatus using the Kamofsky and Eastern Cooperative O nco log y Grou p perform ance statu s scales (de S OIja et aIl 2(1):59-63-oc Impact of severe acute respiratory syndrome o n patient access 10 pal liative radiation therapy [Lee er alJ 2(2 ): I()( ) -113-oc Coifficr,B. O pt imizing mana ge ment of t um o r l ys is s y nd ro m e in adults wi th hemato logic maligna ncies [Michallet et al] 2(3) :159\u00b7166-er Cook, r.c, Survival-adjusted muluple-event analysis for the evaluation of trea tme nt effects of zoled ronic acid in patients with bone metastases from solid tumors IMajorct aI1 2(4) :234 -240-oc Couture, FA. W~kly a.dministration of epoerin alfa impro ves cognition and quality of life In pat ients with bre ast cancer rec eiv ing ch emotherapy [Chang et al] 2(1 ):52-58-oc C r awford. J. Year two for Support;v(' Cancer 77,eTO/')' (Crawford) 2(l):9-IO-ed Exploring the breadth of supportlve cancer cere issues [Crawford] 2(2):77-78-ed Imp roving cl inica l prac tice: the im port ance of gui de li ne deve lop ment [Crawford ) 2(3):135-136-ed Impact of the Multinational Associa tion of Supportive Care in Cancer on Supportive Can cer Therapy [Craw ford12(4):201 .202.ed A combined analysis of average relative dose intens ity in the cbe rnctherapy of sol id tumo rs with pegfilgrastim or filgrastim support (severe acute respir atory syndrome on pa tient acces s to palliative radi ation therapy (Lee et al] 2(2):109-113-oc navis, I.. The correlation amo ng patie nts and health care profe ssionals in assessi ng functional status using the Kam ofsky and Eastern Cooperative O ncology Grou p performance status scales [de Borj a ct al] 2(1 ):59-63\u00b7oc d e Borja. M: I: The correlation among pat ients and health ca re professionals in assessi ng func tional status using the Kamofsky and Eastern Cooperative Oncol ogy Group performance statu s scales [de Borja er al] 2(1):59-63-oc Denson, R. Chemothera py-induced emesis: quality of life and econom ic impact in the context of curre nt practice in Canada [Lachainc et all 2(3): 181 \u00b7 187 Dubois, R.W. Benefits of GM-CSF versus placebo or G\u00b7CSF in reducing che mothe rap yinduced complication s: a systematic review of the literature [Dubois et 01]2(1 ):34-4I -cr Dufour,A. Chemo therapy-induced emesis: quality of life and econom ic impact in the context of current practice in Ca nada [Lachaine et al] 2(3):18 1-187 E Esa na. A. Tumor lysis syndrome in solid tumors [Molt er all 2(3) :188-Fey, E.G. Si ngle-dose preve ntio n or short-term tre atme nt with fibro blast grow th factor-20 (C OSJ I35.QS) reduces th e severity and duration of oral muco sitis (Alvarez el al ) 2(2) : 122-1V -tm Forrest, G.N. Appro aches to management of invasive fungal infectio ns in patient s wit h hemat ologic malig nancies [Forrest and Walsh] 2( 1):2 1\u00b73 0\u00b7c r Fortner, B.V. Sex differen ces in patients who have ca ncer wit h mild ane mia : symptom burden and qual ity of life [Schwartzberg et al) 2(4) :241-246-oc Fo urn ey, n.R. Supportive care aspec ts of vertebroplasty in patients with ca ncer IWu and Fou rney] 2(2):98-104 -cr Fung, K. Impact of severe acute respiratory syndrome on pa tien t access to palliative radi ation therapy (Lee et all 2(2):109-113-oc G Ge rlac h , vt., Single-do se preventi on or s hort-term treat ment with fibroblas t growth factor -20 (CO S3 13S-05) red uces the severity an d duratio n of oral mucositis (Alvare z et all 2(2):122 -12 7-tm Gerwicn, It. W. Single-d ose prever uic n or s ho rt-term treat me nt wit h fibroblast growth facto r-20 (CG53 I35-0S) red uce s the sev eri ty and d uration of oral mucositis [A lvarez.ct al] 2(2 ):122-127-tm (;lllies, C. Th e corre lation among pat ients and hea lth care profession als in assessing functi onal status using the Karno fsky and Eastern Cooperative Onco logy Group performance status scales (de Borja er al) 2( 1):S9\"('3-oc Impact of severe acu te respiratory syndrome on patie nt access 10 palliat ive radiation thera py [lee et al) 2(2) : I09\u00b7 113-oc Glas mac hcr, A. Invasive fungal infection s in patients with hem atologic malignancies: the next steps (Forrest and Walsh) [Glasmacher] 2( J):3 1\u00b733 \u00b7comm Go ld man, S.C. Patient se lect ion and tre atm ent of tumor lysi s syndrome in adults with hematologic malig nancies (Mlcballet et all (Goldm an] 2(3): I67--eomm",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "1):47-51-cr C ritical Cancer Serv ices Impact of severe acute resp iratory syndrome on patient acce ss to pa lliative radiation therapy (Lee et al]2(2):109-1 13-oc Cyt ok in e Si ngle-dose prev entio n o r short -term tr eatment with fibroblast growth ra ndomized , multi center, ope n-label co mparison of t he an tieme tic efficacy of dolasetron versus on dansetron for the prevention of nauseaTumor lysis syndrome in solid tumors [Mou et al] 2(3):188-191-case Emetogen ic C hem othe ra py A ran domi zed . m ult icenter, open-label co mparison o f the an tiemetic effica cy of do laserron vers us ondansetron for the prevent ion of nausea and vom iting during high-dose myeloab lative chemotherapy [Mandanas",
            "latex": null,
            "type": "table"
        },
        "TABREF2": {
            "text": "Tumor lysis syndrome in solid tumors [Mott et al) 2(3):188\u00b7 l9 1-case Hyperuricemia Optimizing ma nageme nt of tumor lysis syndrome in adults with hematologic malignancies (Michallet et al}2(3):159-166-cr Hyperur lcemic Ne ph ropath y Tumor lysis syndrome in solid tumors [MOll et al) 2(3): 188-19 1-case Hypocalcemia Optimizing managem ent of tumor lysis syndro me in adults with hematologic malignancies [Michallet et al) 2(3) :159-J66-cr Tumor lysis syndrome in solid tumors [Ma n et al] 2(3 ): 188-19 1-ca~e Infection Approaches to management of invasive fungal infect ions in patient s with hematologic malig.nancies (Forresl and Wa lsh ] 2( 1):2 1\u00b730<r An overv iew of Ihe management o f infect ion and febr ile neutro pe nia in patients with cancer [Morrisc nl 2(2):88-94-cr Interrater Agreeme nt Invasive funga l infections in pa tients with hema tologic malignancies: the next steps (FOITest and Walsh) [Gl asmachcr] 2( 1):3 1-33\u00b7comm Kamofsky Performan ce Status The correlation am ong pati ent>; and health care profe ssionals in assessing functiona l status using the K arnofsky and Eastern Cooperative Oncology Groupperformance status scales [de BOI j a et al]2(1):59-63 -oc K.lPhopl as ly Support ive care aspec ts of vertc broplasty in patients wi th cancer [Wu and Fourney12",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}